eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | diffuse large b-cell lymphoma |
| Comorbidity | C0334634|mantle cell lymphoma |
| Sentences | 1 |
| PubMedID- 21135857 | However, up to 40% of patients with relapsed diffuse large b-cell nhl (dlbcl) die because of their disease;1 mantle cell lymphoma (mcl) is still not predictably curable,2, 3 and there is substantial need to develop new treatments for transformed lymphoma.4 the pi3k/akt/mtor pathway is a key growth and survival pathway for cancer cells.5, 6, 7 the mammalian target of rapamycin (mtor) kinase, a key member of the pathway, is a 289-kda serine–threonine kinase that exists in mutually exclusive complexes referred to as mtorc1 and mtorc2.8 each complex has several components, one of which is mtor, the catalytic subunit. |
Page: 1